Latest Clinical endpoint Stories
Dignity Sciences today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis
- Study successfully meets primary endpoint- Lack of sleep-related side effects supports flexible nighttime dosing platform to target control over symptoms during the morning routine-
Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global
Streamlined process will improve efficiency and quality of data collection Reston, Virginia (PRWEB) February 25, 2014 Aptiv Solutions, a global biopharmaceutical
Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan.
Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning LOS ANGELES, Jan. 9, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments.
COLORADO SPRINGS, Colo., July 27, 2011 /PRNewswire/ -- Stryker Neurovascular, a division of Stryker Corporation, today announced the results of its Matrix and Platinum Science (MAPS) Trial during the Society of NeuroInterventional Surgery (SNIS) 8th Annual Meeting in Colorado Springs.
BALA CYNWYD, Pa., March 28, 2011 /PRNewswire/ -- Applied Clinical Intelligence, LLC (ACI), an industry leader in clinical endpoint adjudication committees and independent data monitoring committees (www.icommittees.com), announces the opening of registration for a complimentary breakfast seminar in Cambridge, MA.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.